Login / Signup

Antibody responses to SARS-CoV2 are distinct in children with MIS-C compared to adults with COVID-19.

Stuart P WeisbergThomas ConnorsYun ZhuMatthew BaldwinWen-Hsuan LinSandeep WontakalPeter A SzaboSteven B WellsPranay DograJoshua I GrayEmma IdzikowskiFrancesca BovierJulia Davis-PoradaRei MatsumotoMaya Meimei Li PoonMichael P ChaitCyrille MathieuBranka HorvatDidier DecimoZachary C BitanFrancesca La CarpiaStephen A FerraraEmily MaceJoshua MilnerAnne MosconaEldad A HodMatteo PorottoDonna L Farber
Published in: medRxiv : the preprint server for health sciences (2020)
Clinical manifestations of COVID-19 caused by the novel coronavirus SARS-CoV-2 are associated with age. While children are largely spared from severe respiratory disease, they can present with a SARS-CoV-2-associated multisystem inflammatory syndrome (MIS-C) similar to Kawasaki's disease. Here, we show distinct antibody (Ab) responses in children with MIS-C compared to adults with severe COVID-19 causing acute respiratory distress syndrome (ARDS), and those who recovered from mild disease. There was a reduced breadth and specificity of anti-SARS-CoV-2-specific antibodies in MIS-C patients compared to the COVID patient groups; MIS-C predominantly generated IgG Abs specific for the Spike (S) protein but not for the nucleocapsid (N) protein, while both COVID-19 cohorts had anti-S IgG, IgM and IgA Abs, as well as anti-N IgG Abs. Moreover, MIS-C patients had reduced neutralizing activity compared to COVID-19 cohorts, indicating a reduced protective serological response. These results suggest a distinct infection course and immune response in children and adults who develop severe disease, with implications for optimizing treatments based on symptom and age.
Keyphrases